Literature DB >> 19240208

Digoxin, HIF-1, and cancer.

Miguel Lopez-Lazaro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19240208      PMCID： PMC2651277          DOI： 10.1073/pnas.0813047106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  5 in total

1.  Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients.

Authors:  Miguel López-Lázaro; Nuria Pastor; Sami S Azrak; María Jesús Ayuso; Caroline A Austin; Felipe Cortés
Journal:  J Nat Prod       Date:  2005-11       Impact factor: 4.050

2.  Cellular basis for the species differences in sensitivity to cardiac glycosides (digitalis).

Authors:  R S Gupta; A Chopra; D K Stetsko
Journal:  J Cell Physiol       Date:  1986-05       Impact factor: 6.384

Review 3.  Digitoxin as an anticancer agent with selectivity for cancer cells: possible mechanisms involved.

Authors:  Miguel López-Lázaro
Journal:  Expert Opin Ther Targets       Date:  2007-08       Impact factor: 6.902

4.  Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial.

Authors:  Björn Hornestam; Markus Jerling; Mats O Karlsson; Peter Held
Journal:  Eur J Clin Pharmacol       Date:  2003-02-19       Impact factor: 2.953

5.  Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth.

Authors:  Huafeng Zhang; David Z Qian; Yee Sun Tan; Kangae Lee; Ping Gao; Yunzhao R Ren; Sergio Rey; Hans Hammers; Daniel Chang; Roberto Pili; Chi V Dang; Jun O Liu; Gregg L Semenza
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-19       Impact factor: 11.205
  5 in total
  7 in total

1.  Hypoxia-Inducible Factors and Cancer.

Authors:  Jonathan C Jun; Aman Rathore; Haris Younas; Daniele Gilkes; Vsevolod Y Polotsky
Journal:  Curr Sleep Med Rep       Date:  2017-01-28

2.  Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study.

Authors:  Saroj Niraula; Greg Pond; Ronald de Wit; Mario Eisenberger; Ian F Tannock; Anthony M Joshua
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

3.  Repurposing metformin, simvastatin and digoxin as a combination for targeted therapy for pancreatic ductal adenocarcinoma.

Authors:  Shi-He Liu; Juehua Yu; Justin F Creeden; Jeffrey M Sutton; Stephen Markowiak; Robbi Sanchez; John Nemunaitis; Andrea Kalinoski; Jian-Ting Zhang; Robert Damoiseaux; Paul Erhardt; F Charles Brunicardi
Journal:  Cancer Lett       Date:  2020-08-21       Impact factor: 8.679

4.  Two preclinical tests to evaluate anticancer activity and to help validate drug candidates for clinical trials.

Authors:  Miguel López-Lázaro
Journal:  Oncoscience       Date:  2015-02-20

5.  Nicotine promotes proliferation of human nasopharyngeal carcinoma cells by regulating α7AChR, ERK, HIF-1α and VEGF/PEDF signaling.

Authors:  Dingbo Shi; Wei Guo; Wangbin Chen; Lingyi Fu; Jingshu Wang; Yung Tian; Xiangsheng Xiao; Tiebang Kang; Wenlin Huang; Wuguo Deng
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

Review 6.  Evaluating the cancer therapeutic potential of cardiac glycosides.

Authors:  José Manuel Calderón-Montaño; Estefanía Burgos-Morón; Manuel Luis Orta; Dolores Maldonado-Navas; Irene García-Domínguez; Miguel López-Lázaro
Journal:  Biomed Res Int       Date:  2014-05-08       Impact factor: 3.411

Review 7.  Drug Repositioning for Effective Prostate Cancer Treatment.

Authors:  Beste Turanli; Morten Grøtli; Jan Boren; Jens Nielsen; Mathias Uhlen; Kazim Y Arga; Adil Mardinoglu
Journal:  Front Physiol       Date:  2018-05-15       Impact factor: 4.566
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.